Download PDF
Hamostaseologie 1998; 18(02): 61-69
DOI: 10.1055/s-0038-1655333
Übersichtsarbeit/Review Articles
Schattauer GmbH

Hämostasestörungen bei Malignomen

Pathogenese und therapeutische Konsequenzen
H.D. Bruhn
1   Medizinische Universitätsklinik Kiel
,
K.-H. Zurborn
2   Reha-Klinik Ahrenshoop
› Author Affiliations
Further Information

Publication History

Publication Date:
27 June 2018 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Malignome setzen verstärkt gerinnungsaktive Substanzen frei (Tumorzellenthromboplastine), welche bei Tumorpatienten zu einer erhöhten Frequenz thromboembolischer Erkrankungen führen. Chemotherapie und Strahlentherapie erhöhen das Risiko thromboembolischer Komplikationen durch verstärkten Tumorzellzerfall weiterhin. Das durch Tumorzellenthromboplastine vermehrt entstehende Thrombin ist darüber hinaus als Mitogen bei der Tumorzellproliferation bedeutsam. Vor diesem Hintergrund ist zu verstehen, daß in tierexperimentellen und in klinischen Studien versucht wurde, durch eine gerinnungshemmende Behandlung nicht nur die thromboembolischen Komplikationen, sondern auch das Tumorwachstum zu beeinflussen.

Schlüsselwörter

Tumorzellenthromboplastine - erhöhte Frequenz thromboembolischer Erkrankungen bei Tumorpatienten - Thrombin als Mitogen - Einflüsse einer gerinnungshemmenden Behandlung auf das Tumorwachstum
 

  • LITERATUR

  • 1 Ambrus JL, Ambrus CM. Blood Coagulation in Neoplastic Disease. In: Onkohämostaseologie. Gastpar H. (ed) Stuttgart-New York: Schattauer; 1976: 167-93.
    Google Scholar
  • 2 Andoh K, Kubota T, Takada M. et al. Tissue factor activity in leukemic cells. Special reference to disseminated intravascular coagulation. Cancer 1987; 59: 748-54.
    PubMedGoogle Scholar
  • 3 Avvisati G, Ten Cate JW, Böller HR, Mandelli F. Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet 1989; i: 122-4.
    PubMedGoogle Scholar
  • 4 Bennett B, Booth NA, Croll A, Dawson AA. The bleeding disorder in acute promyelocytic leukemia: fibrinolysis due to u-PA rather than defibrination. Br J Haematol 1989; 71: 511-5.
    CrossrefPubMedGoogle Scholar
  • 5 Berger H, Freudenberg N. Todesursachen bei Malignompatienten. Med Welt 1983; 34: 112-8.
    PubMedGoogle Scholar
  • 6 Bern MM, Lokich JJ, Wallach SR. et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Int Med 1990; 112: 423-8.
    PubMedGoogle Scholar
  • 7 Bick RL. Alterations of Hemostasis Associated with Malignancy: Etiology, Pathophysiology, Diagnosis and Management. Semin Thromb Hemost 1978; 05: 1-26.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Bruhn HD, Zurborn KH. Influence of clotting factors (thrombin, factor XIII) and of fibronectin on the growth of tumor cells and leukemic cells in vitro. Blut 1983; 46: 85-8.
    CrossrefPubMedGoogle Scholar
  • 9 Bruhn HD, Knapp S, Senger H. et al. Auswirkungen einer Strahlen-oder Zytostatikatherapie auf das Hämostasesystem. In: Tilsner V, Matthias FR. (eds) Blutgerinnung und Onkologie. XXXI. Hamburger Symposion über Blutgerinnung; Editiones Roche, Basel: 1988: 171.
    Google Scholar
  • 10 Bruhn HD, Zurborn KH. Veränderungen des Hämostasesystems bei malignen Erkrankungen und deren klinische Bedeutung. In: Spanuth E. (ed) Malignome und Hämostase. Springer, Berlin; Heidelberg, New York: 1996: 3-15.
    Google Scholar
  • 11 Chahinian AP, Propert KJ, Ware JH. et al. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol 1989; 07: 993-1002.
    CrossrefPubMedGoogle Scholar
  • 12 Clarke-Pearson DL, Synan IS, Creasman WT. Anticoagulation therapy for venous thromboembolism in patients with gynecologic malignancy. Am J Ostet Gynecol 1983; 147: 369-75.
    CrossrefPubMedGoogle Scholar
  • 13 Cohen JR, Tenenbaum N, Citron M. Greenfield filter as primary therapy for deep venous thrombosis and/or pulmonary embolism in patients with cancer. Surgery 1991; 109: 12-5.
    PubMedGoogle Scholar
  • 14 Costantini V, Zacharski LR. Fibrin and Cancer. Thromb Haemost 1993; 69: 406-14.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 de Jong E, Knot EAR, Piket D. et al. Increased Plasminogen Activator Inhibition Levels in Malignancy. Thromb Haemostas 1987; 57: 771-82.
    PubMedGoogle Scholar
  • 16 Donate MB, Falanga A, Consonni R. et al. Cancer procoagulant in acute non lymphoid leukemia: Relationship of enzyme detection to disease activity. Thromb Haemostas 1990; 64: 11-6.
    PubMedGoogle Scholar
  • 17 Duffy MJ, O’Grady P. Plasminogen activator and cancer. Perspectives and commentaries. Eur J Cancer Clin Oncol 1984; 20: 577-82.
    PubMedGoogle Scholar
  • 18 Dvorak HF. Thrombosis and Cancer. Hum Pathol 1987; 18: 275-84.
    CrossrefPubMedGoogle Scholar
  • 19 Drapkin RL, Gee TS, Dowling MD. et al. Prophylactic Heparin Therapy in Acute Promyelocytic Leukemia. Cancer 1978; 41: 2484-90.
    CrossrefPubMedGoogle Scholar
  • 20 Edwards RL, Silver J, Rickies FR. Human Tumor Procoagulants: Registry of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee, International Society on Thrombosis and Haemostasis. Thromb Haemost 1993; 69: 205-13.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Francis JL. Haemostasis and cancer. Med Lab Sei 1989; 46: 331-46.
    PubMedGoogle Scholar
  • 22 Gasic GJ, Gasic TB, Galanti N. et al. Platelet-tumor-cell interactions in mice. Int J Cancer 1973; 11: 704-18.
    CrossrefPubMedGoogle Scholar
  • 23 Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sei USA 1968; 61: 46-52.
    CrossrefPubMedGoogle Scholar
  • 24 Gastpar H. Beeinflussung der Metastasierung durch Hemmung der Thrombozytenaggregation. Beitr Onkol 1982; 13: 290-306.
    PubMedGoogle Scholar
  • 25 Goerner A. The influence of anticlotting agents on transplantation and growth of tumor tissue. J Lab Clin Med 1930; 16: 369-72.
    PubMedGoogle Scholar
  • 26 Gordon SG. Tumorprokoagulans, Gerinnung und Fibrinolyse bei malignen Erkrankungen. Hämostaseologie 1985; 05: 160-5.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Gralnick HR, Abrell E. Studies of the Procoagulant and Fibrinolytic Activity of Promyelocytes in Acute Promyelocytic Leukaemia. Br J Haematol 1973; 24: 89-99.
    CrossrefPubMedGoogle Scholar
  • 28 Guarini A, Gugliotta L, Timoncini C. et al. Procoagulant cellular activity and disseminated intravascular coagulation in acute non-lymphoid leukaemia. Scand J Haematol 1985; 34: 152-6.
    PubMedGoogle Scholar
  • 29 Hagedorn AB, Bowie EJW, Elveback LR, Owen CA. Coagulation abnormalities in patients with inoperable lung cancer. Mayo Clin Proc 1074; 49: 649-53.
    PubMedGoogle Scholar
  • 30 Hilgard P. Tumorausbreitung und Metastasierung als Indikation für Antikoagulation und Fibrinolysetherapie. In: Gastpar H. (ed) Onkohämostaseologie. Stuttgart-New York: Schattauer; 1976: 107-9.
    Google Scholar
  • 31 Honn KV, Cicone B, Skoff A. Prostacyclin: a potent antimetastatic agent. Sience 1981; 212: 1270-2.
    CrossrefPubMedGoogle Scholar
  • 32 Kutti J. The management of thrombocytosis. Eur J Haematol 1990; 44: 81-8.
    PubMedGoogle Scholar
  • 33 Kwaan HC, Keer HN. Fibrinolysis in cancer. Semin Thromb Hemost 1990; 16: 230-5.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 34 Levine MN, Gent M, Hirsh J. et al. The Thrombogenic Effect of Anticancer Drug Therapy in Women with Stage II Breast Cancer. N Engl J Med 1988; 318: 404-7.
    CrossrefPubMedGoogle Scholar
  • 35 Levine MN, Hirsh J, Gent M. et al. Doubleblind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343: 886-9.
    CrossrefPubMedGoogle Scholar
  • 36 Licciardello JTW, Moake JL, Rudy ChK. et al. Elevated Plasma von Willebrand Factor Levels and Arterial Occlusive Complications Associated with Cisplatin-Based Chemotherapy. Oncology 1985; 42: 296-300.
    CrossrefPubMedGoogle Scholar
  • 37 Lohrmann HP, Adam W, Heymer B, Kubanek B. Microangiopathic hemolytic anemia in metastatic carcinoma. Report of eight cases. Ann Intern Med 1973; 79: 368-75.
    PubMedGoogle Scholar
  • 38 Ludwig H. Anticoagulantien beim fortgeschrittenen Carcinom. Gynäkologe 1974; 07: 204-12.
    PubMedGoogle Scholar
  • 39 Markus G. The role of haemostasis and fibrinolysis in the metastatic spread of cancer. Semin Thromb Haemost 1984; 10: 61-70.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 40 Moore FD, Osteen RT, Karp DD. et al. Anticoagulants, venous thromboembolism, and the cancer patient. Arch Surg 1981; 116: 405-7.
    CrossrefPubMedGoogle Scholar
  • 41 Nanninga PB, van Teunenbroek A, Veenhof CHN. et al. Low prevalence of coagulation and fibrinolytic activation in patients with primary untreated cancer. Thromb Haemost 1990; 64: 361-4.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 42 Nordstrom M, Lindblad B, Anderson H, Kjellström T. Deep venous thrombosis and occult malignancy: an epidemiological study. Br Med J 1994; 308: 891-4.
    CrossrefPubMedGoogle Scholar
  • 43 Pearlstein E, Salk PL, Yogeeswaran G, Karpatkin S. Correlation between spontaneous metastastic potential platelet aggregating activity of cell surface extracts and cell surface sialylation in 10 metastatic variant derivatives of a rat renal sarcoma cell line. Proc Natl Acad Sei USA 1980; 77: 4336-9.
    CrossrefPubMedGoogle Scholar
  • 44 Peuscher FW, Cleton FJ, Armstrong L. et al. Significance of plasma fibrinopeptide A (fpA) in patients with malignancy. J Lab Clin Med 1980; 96: 5-14.
    PubMedGoogle Scholar
  • 45 Poller L, McKernan A, Thomson JM. et al. Fixed mini-dose warfarin: a new approach to prophylaxis against venous thrombosis after major surgery. Br Med J 1987; 295: 1309-12.
    CrossrefPubMedGoogle Scholar
  • 46 Prandoni P, Lensing AWA, Biiller HR. et al. Deep-Vein Thrombosis and the Incidence of Subsequent Symptomatic Cancer. N Engl J Med 1992; 327: 1128-33.
    CrossrefPubMedGoogle Scholar
  • 47 Rasche H, Dietrich M. Hemostatic abnormalities associated with malignant diseases. Europ J Cancer 1977; 13: 1053-64.
    CrossrefPubMedGoogle Scholar
  • 48 Rickies FR, Edwards RL. Activation of Blood Coagulation in Cancer: Trousseau’s Syndrome Revisited. Blood 1983; 62: 14-31.
    PubMedGoogle Scholar
  • 49 Rickies FR, Levine M, Edwards RL. Hemostatic alterations in cancer patients. Cancer Metast Rev 1992; 11: 237-48.
    CrossrefPubMedGoogle Scholar
  • 50 Sarasin FP, Eckman MH. Management and prevention of thromboembolic events in patients with cancer-related hypercoagulability states: a risky business. J Gen Intern Med 1993; 08: 476-86.
    CrossrefPubMedGoogle Scholar
  • 51 Schafer AI. Bleeding and thrombosis in myeloproliferative disorders. Blood 1984; 64: 1-22.
    PubMedGoogle Scholar
  • 52 Schmidt MB. Die Verbreitungswege der Karzinome und die Beziehungen generalisierter Sarkome zu den leukämischen Neubildungen. Fischer: Jena; 1903
    Google Scholar
  • 53 Schneider W. Bedeutung von Hämostasestörungen für Diagnostik und Therapie von Tumorkrankheiten. Hämostaseologie 1988; 08: 34-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 54 Schöndorf TH, Witt I. Protein C in patients under L-asparaginase treatment. In: Witt I. (ed) Protein C-Biochemical and Medical Aspects. Walter de Gruyter; Berlin New York: 1985: 125-34.
    Google Scholar
  • 55 Südhoff T, Schneider W. Fibrinolytic mechanisms in tumor growth and spreading. Clin Investig 1992; 70: 631-5.
    PubMedGoogle Scholar
  • 56 Sun NC, McAffee WM, Hum GJ. et al. Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Am J Clin Pathol 1979; 71: 10-9.
    CrossrefPubMedGoogle Scholar
  • 57 Sutor AH, Ritter J. Thrombosen bei Kindern mit akuter lymphatischer Leukämie. Hämostaseologie 1992; 12: 107-15.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 58 Tanaka H, Narahara N, Kurabayashi H. et al. Studies on leukemic cell tissue factor. Thromb Res 1989; 53: 535-49.
    CrossrefPubMedGoogle Scholar
  • 59 Terranova T, Chiossone F. II fattore coagulazione nell’attecchimento delle cellule neoplastiche immesse in circolo. Boll Soc Ital Biol Sper 1952; 28: 1224-5.
    PubMedGoogle Scholar
  • 60 Trousseau A. Phlegmasia alba dolens. Clinique médicale de l’hotel-dieu de Paris. The New Sydenham Society; London: 1865: 3-94.
    Google Scholar
  • 61 Wehmeier A, Schneider W. Megakaryocytes and platelets as the main cause for vascular events in chronic myeloproliferative disease. Hämostaseologie 1996; 16: 151-63.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 62 Weiss RB, Tormey DC, Holland JF, Weinberg VE. Venous Thrombosis During Multimodal Treatment of Primary Breast Carcinoma. Cancer Treat Rep 1981; 65: 677-9.
    PubMedGoogle Scholar
  • 63 Zacharski LR, Henderson WG, Rickies FE. et al. Effect of warfarin anticoagulation on survival in carcinoma of lung, colon, head and neck and prostate: final report of VA cooperative study #75. Cancer 1984; 53: 2046-52.
    CrossrefPubMedGoogle Scholar
  • 64 Zacharski LR, Costantini V, Wojtukiewicz MZ. Anticoagulants as Cancer Therapy. Sem Oncol 1990; 17: 217-27.
    PubMedGoogle Scholar
  • 65 Zacharski LR, Donati MB, Rickies FR. Registry of clinical trials of antithrombotic drugs in cancer: second report. Thromb Haemost 1993; 70: 357-60.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 66 Zurborn K-H, Duscha H, Gram J, Bruhn HD. Investigations of Coagulation System and Fibrinolysis in Patients with Disseminated Adenocarcinomas and Non-Hodgkin’s Lymphomas. Oncology 1990; 47: 376-80.
    CrossrefPubMedGoogle Scholar
  • 67 Zurborn K-H, Gram J, Glander K. et al. Influence of cytostatic treatment on the coagulation system and fibrinolysis in patients with non-Hodgkin’s lymphomas and acute leukemias. Eur J Haematol 1991; 47: 55-9.
    CrossrefPubMedGoogle Scholar
  • 68 Zurborn K-H. Hemostasis and hormonal tumor therapy: epidemiology and clinical studies. Gynecol Endocrinol 1993; 07 (Suppl.) 1-5.
    PubMedGoogle Scholar